Cargando…
Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms
Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated that MSCs can improve disease outcome when ‘activated' to exert immunomodulatory effects. However, the precise mechanisms modulating MSC-immune cells interactions remain largely elusive. In here, we ac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972508/ https://www.ncbi.nlm.nih.gov/pubmed/24691433 http://dx.doi.org/10.1038/srep04565 |
_version_ | 1782309601289437184 |
---|---|
author | Kota, Daniel J. DiCarlo, Bryan Hetz, Robert A. Smith, Philippa Cox, Charles S. Olson, Scott D. |
author_facet | Kota, Daniel J. DiCarlo, Bryan Hetz, Robert A. Smith, Philippa Cox, Charles S. Olson, Scott D. |
author_sort | Kota, Daniel J. |
collection | PubMed |
description | Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated that MSCs can improve disease outcome when ‘activated' to exert immunomodulatory effects. However, the precise mechanisms modulating MSC-immune cells interactions remain largely elusive. In here, we activated MSC based on a recent polarization paradigm, in which MSCs can be polarized towards a pro- or anti-inflammatory phenotype depending on the Toll-like receptor stimulated, to dissect the mechanisms through which MSCs physically interact with and modulate leukocytes in this context. Our data show that MSCs activated through the Toll-like receptor (TLR) 4 pathway increased VCAM-1 and ICAM-1 dependent binding of leukocytes. On the other hand, TLR3 stimulation strongly increases leukocytes affinity to MSC comparatively, through the formation of cable-like hyaluronic acid structures. In addition, TLR4 activation elicited secretion of pro-inflammatory mediators by MSCs, whereas TLR3-activated MSCs displayed a milder pro-inflammatory phenotype, similar to inactivated MSCs. However, the differently activated MSCs maintained their ability to suppress leukocyte activation at similar levels in our in vitro model, and this immunomodulatory property was shown here to be partially mediated by prostaglandin. These results reinforce the concept that alternate activation profiles control MSC responses and may impact the therapeutic use of MSCs. |
format | Online Article Text |
id | pubmed-3972508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-39725082014-04-02 Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms Kota, Daniel J. DiCarlo, Bryan Hetz, Robert A. Smith, Philippa Cox, Charles S. Olson, Scott D. Sci Rep Article Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated that MSCs can improve disease outcome when ‘activated' to exert immunomodulatory effects. However, the precise mechanisms modulating MSC-immune cells interactions remain largely elusive. In here, we activated MSC based on a recent polarization paradigm, in which MSCs can be polarized towards a pro- or anti-inflammatory phenotype depending on the Toll-like receptor stimulated, to dissect the mechanisms through which MSCs physically interact with and modulate leukocytes in this context. Our data show that MSCs activated through the Toll-like receptor (TLR) 4 pathway increased VCAM-1 and ICAM-1 dependent binding of leukocytes. On the other hand, TLR3 stimulation strongly increases leukocytes affinity to MSC comparatively, through the formation of cable-like hyaluronic acid structures. In addition, TLR4 activation elicited secretion of pro-inflammatory mediators by MSCs, whereas TLR3-activated MSCs displayed a milder pro-inflammatory phenotype, similar to inactivated MSCs. However, the differently activated MSCs maintained their ability to suppress leukocyte activation at similar levels in our in vitro model, and this immunomodulatory property was shown here to be partially mediated by prostaglandin. These results reinforce the concept that alternate activation profiles control MSC responses and may impact the therapeutic use of MSCs. Nature Publishing Group 2014-04-02 /pmc/articles/PMC3972508/ /pubmed/24691433 http://dx.doi.org/10.1038/srep04565 Text en Copyright © 2014, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images in this article are included in the article's Creative Commons license, unless indicated otherwise in the image credit; if the image is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the image. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Article Kota, Daniel J. DiCarlo, Bryan Hetz, Robert A. Smith, Philippa Cox, Charles S. Olson, Scott D. Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms |
title | Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms |
title_full | Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms |
title_fullStr | Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms |
title_full_unstemmed | Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms |
title_short | Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms |
title_sort | differential msc activation leads to distinct mononuclear leukocyte binding mechanisms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972508/ https://www.ncbi.nlm.nih.gov/pubmed/24691433 http://dx.doi.org/10.1038/srep04565 |
work_keys_str_mv | AT kotadanielj differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms AT dicarlobryan differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms AT hetzroberta differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms AT smithphilippa differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms AT coxcharless differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms AT olsonscottd differentialmscactivationleadstodistinctmononuclearleukocytebindingmechanisms |